Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
BETHESDA, Md., Oct. 25, 2017 -- India Globalization Capital, Inc. (NYSE MKT:IGC) announced that it has entered into a Memorandum of Understanding (MOU) with MediCann Handels GmbH, a company based in Hamburg Germany, for the import and distribution of IGC’s cannabinoid based therapies including IGC-AD1 (Hyalolex) to pharmacies in Germany.
MediCann plans to distribute to pharmacies, apothecaries and other licensed retail outlets that are legally allowed to sell cannabinoid-based products. Under the current MOU, MediCann will provide the capital required for the transportation, import, storage, sales and marketing of products intended for the German market. The agreement is subject to standard closing conditions such as due diligence relating to satisfactory licensing and product procurement.
“There are many benefits to developing a strong presence in the German pharmacy market including, a favorable regulatory environment and reimbursement from health insurance providers. The agreement with MediCann is the first step in the commercialization process of our therapies, as we work out the logistics of how to efficiently deliver our products to Germany," states Ram Mukunda, CEO. “We are glad to add the products of IGC to our portfolio. With these products we will have a unique selling point in the German market,” states Carsten Siegemund, CEO of MediCann.
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA.
For more information please visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/
Forward-looking Statements
Please see forward looking statements as discussed in detail in IGC's Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.
Contact:
Claudia Grimaldi
301-983-0998
